Nerve Regeneration

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1906

Special Issue Editors


E-Mail Website
Guest Editor
Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italy
Interests: regenerative surgery; tissue imaging; laparoscopic surgery; nerve regeneration

E-Mail Website
Guest Editor
Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Section of Human Anatomy, “Sapienza” University of Rome, Via A. Borelli 50, 00161 Rome, Italy
Interests: cell death; autophagy; cancer growth; organ homeostasis; tissue regeneration
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Molecular and Translational Medicine, Center of Emphasis in Diabetes and Metabolism, Texas Tech University Health Sciences Center, 5001 El Paso Drive, El Paso, TX 79905, USA
Interests: tissue engineering; inflammation; nerve regeneration; stem cells; gene therapy; cardiac tissue
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nerve regeneration is a critical process involving the repair and restoration of damaged nerves, which is essential for functional recovery in patients with traumatic nerve injuries, neurodegenerative diseases, and other neurological disorders. As a complex and intricate biological process, nerve regeneration presents significant challenges in terms of understanding the underlying mechanisms, developing effective therapeutic strategies, and achieving successful clinical outcomes.

This Special Issue aims to provide a platform for researchers, clinicians, and experts in the field of bioengineering to share the latest advances, cutting-edge technologies, and innovative approaches in nerve regeneration research. Topics of interest include, but are not limited to, nerve tissue engineering, biomaterials for nerve repair, stem cell-based therapies, nerve guidance conduits, neuroprosthetics, and bioelectronic medicine.

By bringing together multidisciplinary perspectives and collaborative efforts, this Special Issue seeks to advance our knowledge and capabilities in promoting nerve regeneration and improving the quality of life for patients with neurological disorders. We invite researchers to contribute original research articles, reviews, and perspectives that address the challenges and opportunities in nerve regeneration, with the ultimate goal of translating scientific discoveries into clinical applications.

Dr. Luca Cicero
Dr. Claudia Giampietri
Dr. Munmun Chattopadhyay
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nerve regeneration
  • neuroengineering
  • biomaterials
  • stem cells
  • neuroprosthetics
  • biomedical devices

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2968 KB  
Article
Engineered Neural Tissue (EngNT) Containing Human iPSC-Derived Schwann Cell Precursors Promotes Axon Growth in a Rat Model of Peripheral Nerve Injury
by Rebecca A. Powell, Emily A. Atkinson, Poppy O. Smith, Rickie Patani, Parmjit S. Jat, Owein Guillemot-Legris and James B. Phillips
Bioengineering 2025, 12(9), 904; https://doi.org/10.3390/bioengineering12090904 - 23 Aug 2025
Viewed by 822
Abstract
Tissue engineering has the potential to overcome the limitations of using autografts in nerve gap repair, using cellular biomaterials to bridge the gap and support neuronal regeneration. Various types of therapeutic cells could be considered for use in aligned collagen-based engineered neural tissue [...] Read more.
Tissue engineering has the potential to overcome the limitations of using autografts in nerve gap repair, using cellular biomaterials to bridge the gap and support neuronal regeneration. Various types of therapeutic cells could be considered for use in aligned collagen-based engineered neural tissue (EngNT), including Schwann cells and their precursors, which can be derived from human induced pluripotent stem cells (hiPSCs). Using Schwann cell precursors may have practical advantages over mature Schwann cells as they expand readily in vitro and involve a shorter differentiation period. However, the performance of each cell type needs to be tested in EngNT. By adapting established protocols, hiPSCs were differentiated into Schwann cell precursors and Schwann cells, with distinctive molecular profiles confirmed using immunocytochemistry and RT-qPCR. For the first time, both cell types were incorporated into EngNT using gel aspiration–ejection, a technique used to align and simultaneously stabilise the cellular hydrogels. Both types of cellular constructs supported and guided aligned neurite outgrowth from adult rat dorsal root ganglion neurons in vitro. Initial experiments in a rat model of nerve gap injury demonstrated the extent to which the engrafted cells survived after 2 weeks and indicated that both types of hiPSC-derived cells supported the infiltration of host neurons, Schwann cells and endothelial cells. In summary, we show that human Schwann cell precursors promote infiltrating endogenous axons in a model of peripheral nerve injury to a greater degree than their terminally differentiated Schwann cell counterparts. Full article
(This article belongs to the Special Issue Nerve Regeneration)
Show Figures

Graphical abstract

14 pages, 1327 KB  
Article
Exploration of Cytokines That Impact the Therapeutic Efficacy of Mesenchymal Stem Cells in Alzheimer’s Disease
by Herui Wang, Chonglin Zhong, Yi Mi, Guo Li, Chenliang Zhang, Yaoyao Chen, Xin Li, Yongjun Liu and Guangyang Liu
Bioengineering 2025, 12(6), 646; https://doi.org/10.3390/bioengineering12060646 - 12 Jun 2025
Viewed by 774
Abstract
Current therapies for Alzheimer’s disease (AD) includes acetylcholinesterase inhibitors, NMDA receptor antagonists, and amyloid beta (Aβ)/Tau-targeting drugs. While these drugs improve cognitive decline and target the pathological mechanisms, their outcomes still are still in debate. Mesenchymal stem cells (MSCs) offer a regenerative approach [...] Read more.
Current therapies for Alzheimer’s disease (AD) includes acetylcholinesterase inhibitors, NMDA receptor antagonists, and amyloid beta (Aβ)/Tau-targeting drugs. While these drugs improve cognitive decline and target the pathological mechanisms, their outcomes still are still in debate. Mesenchymal stem cells (MSCs) offer a regenerative approach by modulating neuroinflammation and promoting neuroprotection. Although the paracrine of MSCs is efficient in various AD preclinical studies and the exosomes of MSCs have entered clinical trials, the key cytokines driving the efficacy remain unclear. Here, we evaluated human umbilical cord-derived MSCs (hUC-MSCs) and employed gene-silenced MSCs (siHGF-MSCs, siTNFR1-MSCs, siBDNF-MSCs) in APP/PS1 AD mice to investigate specific mechanisms. hUC-MSCs significantly reduced Aβ/Tau pathology and neuroinflammation, with cytokine-specific contributions: silencing HGF predominantly reduced Aβ/Tau clearance, although silencing TNFR1 or BDNF showed modest effects; silencing TNFR1 or BDNF more prominently weakened anti-neuroinflammation, while silencing HGF exerted a weaker influence. All three cytokines partially contributed to oxidative stress reduction and cognitive improvements. Our study highlights MSC-driven AD alleviation as a multifactorial strategy and reveals specific cytokines alleviating different aspects of AD pathology. Full article
(This article belongs to the Special Issue Nerve Regeneration)
Show Figures

Graphical abstract

Back to TopTop